Random 2 Flashcards

1
Q

ANC equation

A

ANC = WBC * (% seg neuts + % bands)

Neutropenia ANC < 500
Must have ANC > 1500 to be eligible for chemotherapy

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
2
Q

Dexrazoxane

A

Prevent cardiomyopathy in doxorubicin > 300 mg/m2
Give 10% of doxo dose as dexrazoxane

Also used for extravasation

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
3
Q

Amifostine

A

Use for nephrotoxicity from cisplatin

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
4
Q

Leucovorin

A

Use after MTX doses > 1000, rescue tx in MTX > 500

Can add on glucarpidase but do not administer leucovorin 2 hours before or afterwards

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
5
Q

Tumor lysis syndrome

A

Rasburicase tx, use allopurinol or fluids as prophylaxis

Increased uric acid

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
6
Q

Hypercalcemia (cancer related)

A

Ca > 14

Fluids, loop diuretics, bisphosphonates, calcitonin

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
7
Q

Corrected Ca equation

A

= (4-albumin)* 0.8 + Ca
Normal is 12-14

use if albumin < 3.5

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
8
Q

Leapfrog Hospital Safety Grades

A

VA hospitals, critical access hospital excluded
Issued 2x per year
Barcode scanning on med admin one of the criteria - goal is to reduce preventable mistakes

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
9
Q

HEDIS

A

NCQA - part of CMS

Not required to report to HEDIS, but used for ratings

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
10
Q

IRB required members

A

5 members

1 scientific, 1 nonscientic, 1 not affiliated with org, and one that represents perspectives of research participants

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
11
Q

Cost Benefit
Cost effectiveness
Cost minimize
cost utilization

A

Cost Benefit: Looks at tx + costs saved with benefit outcomes
Cost effectiveness: Looks at measured clinical uses or outcomes (years of lives saved)
Cost minimize: Compares therapies
Cost utilization: Looks at mortality / QALY

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
12
Q

ivabradine (Corlanor)

A

Used in HF EF < 35% and on max tolerated BB with HR > 70 bmp.
ADE: bradycardia, atrial fibrillation, HTN
Lowers hospitalizations

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
13
Q

Criteria for antibiotics in COPD

A

Dyspnea OR increase sputum volume
+ increased sputum purulence

OR mechanical ventilation

Augmentin, macrolide, doxycyline if GOLD 1 or 2
Levo/cipro if GOLD 3 or 4 (pseudo coverage)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
14
Q

Theoyphilline

A

MOA - phosphodiesterase inhibitor, methylxanthine. No longer recommended for acute tx of asthma

Can lower seizure threshold

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
15
Q
FEV cut-off's
GOLD 1
GOLD 2
GOLD 3
GOLD 4
A

GOLD 1 >= 80%
GOLD 2 50-79%
GOLD 3 30-49%
GOLD 4 < 30%

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
16
Q

Pneumococcal vaccine recommendations

A

Age 19-64 w/ chronic medical condition (give if FEV1 < 40%) - 1 dose of PPSV23

Immunocompromised > 19 yoa: 1 dose PPSV13, 8 weeks later PPSV23, then 5 years later booster PPSV23

65 and older - PPSV 13 and PPSV 23 one year later

17
Q

Hyponatremia

A

If due to dehydration, give NaCl 0.9%, check in q4h
Na < 120, symptomatic - use hypertonic saline NaCl 3%
1 mEq/L/hr (severe), 0.5 mEq/L/hr in moderate. Can give NaCl 0.45% to slow down the rise.

Do not correct more than 10-12mEq per 24 hours, or > 18 mEq in 48 hours.

Treating hypokalemia will help increase Na as well! If Euvolemic or edematous, fluid restriction (<800mL/day) or vasopressin antagonists like tolvaptan

Med induced = thiazides, antiepileptics, SSRI’s, hypothyroid, SIADH

18
Q

Hypernatremia

A

Na > 145 - caused by dehydration, sodium retention, brain injuries. Requires H2O! Must give by mouth or via D5W, never SW infusion!
If hypotensive, can give NaCl 0.9%

19
Q

Hypokalemia

A

K < 3.5
Causes: insulin, beta agonists (albuterol), alkalosis, hypothermia, diuretics, GI losses

K 3-3.5 –> PO KCl 40-80 mEq/day
K 2-3 –> IV or PO (IV 10-20 mEq/hr)
K < 2 give 20 - 40 mEq/hr IV (ECG monitor)

Divide doses > 60 mEq to reduce GI SE
Max peripheral IV is 60-80 mEq
Don’t mix K in dextrose

20
Q

Hyperkalemia

A

K > 5; if > 6.5 it is an emergency !
If symptomatic:
- Calcium gluc 1 g IV push to reduce cardiac risk
- Insulin 10 units IV + 25-50 g glucose via 50% IVpush
- Sodium bicarbonate 50 mEq IV push
- Albuterol 10-20 mg neb (if on BB, pt will not respond - not as effective)

If asx, give sodium polystyrene sulfonate alone 15 g q6h

Causes: succ, K sparing diuretics, acei, arbs, trimethoprim. If CAD, CHF, DM - higher risk of sudden death

21
Q

Hypomagnesium / hypermagnesium

A

Mg < 1.7
Oral supplementation, mag oxide - SE is diarrhea
1-4 g slow IV infusion, lower dose by 50% in renal
Can give push if emergency

Mg > 2.3
0.9% NaCl, loops, IV calcium if sx

22
Q

Hypocalcemia

A
Corrected Ca if Ca < 8.5
Sx: muscle twitch/seizure
CaCl 1g via central line
CaGluc 2-3 g via peripheral line
max rate 60 mg/min
23
Q

Hyperpcalcemia

A

Due to malignancy: NaCl 0.9% plus bisphosphonate (zolendronic acid 4 mg IV - can take up to 7 days for nadir to be reached) + calcitonin (if symptomatic)

24
Q

Medicare Access and CHIP Reauth Act (MACRA)

A

Fee for service to a value-based or pay for performance model

25
NDA ANDA INDA
NDA - Submitted after Phase III studies before market approval ANDA - generic drugs, submitted 3-5 years after market exclusivity by brand company. Retain a 180 day exclusivity of generic product. INDA - used for new drug, new indication, off-label use. Must be submitted after pre-clinical trials, before Phase I trials.
26
Orange Book
A - both pharmaceutical equivalents and bioequivalent, may be interchanged B - pharmaceutical equivalents only, cannot be interchanged Biosimilars - purple book, availavlee for biological products after 12 years exclusivity
27
Medwatch Form FDA 3500, 3500A, 3500B
Form 3500 - voluntary reporting by HCP, can disclose PHI Form 3500A - IND reporters, manufacturers, distributors, etc Form 3500B - Consumers and patients
28
HITECH Act
Promote healthcare information tech, authorizes DHHS to promote CMS gives financial incentives for "meaninful use" of EMR (under ARRA)
29
Orphan Drug Act
Grants, assistance, for patient populations of < 200,000 Grants market exclusivity for 7 years after FDA approval Grants 20 year patent life (starts when molecule is invented)
30
New Drug Process
Preclinical trials > INDA > Phase I: PK/PD in ~ 50 human volunteers > Phase 2: Indication for drug in several hundred patients > Phase 3: Efficacy and safety evaluation > NDA > Phase 4: Postmarketing studies
31
Drug causes of SIADH
SSRI's Carbamazepine Barbiturates Narcotics